{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:10:57Z","timestamp":1762445457611,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To examine whether adherence to a low-iodine diet (LID) enhances the therapeutic efficacy of radioiodine therapy (RAI) in Graves\u2019 hyperthyroidism (GH) in iodine-rich areas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively evaluated 185 patients with GH from Aichi (n\u2009=\u2009114) and Hokkaido (n\u2009=\u200971) Prefectures. Patients aged\u2009\u2265\u200918\u00a0years with GH who underwent RAI between December 2012 and March 2022 were divided into subgroups based on pretreatment with anti-thyroid drug (ATD) or potassium iodide (KI). Patients were followed up with LID from 18\u00a0days (group A) or 7\u00a0days (group H) before RAI to 3\u00a0days after RAI. The dose of radioactive iodine 131 (<jats:sup>131<\/jats:sup>I) was adjusted to deliver\u2009&gt;\u2009100\u00a0Gy to the thyroid. The associations between urinary iodine concentration on UIC2 vs. 24hRU and UIC2 vs. the 1-year RAI success rate (SR) were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with UIC1, UIC2 was significantly decreased in all subgroups (P\u2009&lt;\u20090.01). An inverse correlation between UIC2 and 24hRU was observed in the four groups; however, the difference was insignificant. The SR in groups A and H was 85% and 89%, respectively. Univariate analysis revealed no association between UIC2 and SR in each group. Additionally, stratification of the 185 patients into quartiles using UIC2 yielded no significant differences in SR (<jats:italic>p<\/jats:italic>\u2009=\u20090.79).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>LID sufficiently reduced UIC in patients undergoing RAI. Although a lower UIC2 may increase 24hRU, it did not increase the success of RAI. The benefit of LID in enhancing the efficacy of RAI in GH treatment remains uncertain.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06523-7","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T04:12:09Z","timestamp":1701058329000},"page":"1060-1069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas"],"prefix":"10.1007","volume":"51","author":[{"given":"Mika","family":"Tamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-9319","authenticated-orcid":false,"given":"Katsuhiko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"6523_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/1450-1147.167584","volume":"15","author":"AH Kartamihardja","year":"2016","unstructured":"Kartamihardja AH, Massora S. The influence of antithyroid drug discontinuation to the therapeutic efficacy of (131)I in hyperthyroidism. World J Nucl Med. 2016;15:81\u20134. https:\/\/doi.org\/10.4103\/1450-1147.167584.","journal-title":"World J Nucl Med"},{"key":"6523_CR2","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1210\/jcem.86.8.7781","volume":"86","author":"A Allahabadia","year":"2001","unstructured":"Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86:3611\u20137. https:\/\/doi.org\/10.1210\/jcem.86.8.7781.","journal-title":"J Clin Endocrinol Metab"},{"key":"6523_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1385\/endo:25:1:55","volume":"25","author":"C Erem","year":"2004","unstructured":"Erem C, Kandemir N, Hacihasanoglu A, Ers\u00f6z HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine. 2004;25:55\u201360. https:\/\/doi.org\/10.1385\/endo:25:1:55.","journal-title":"Endocrine"},{"key":"6523_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1530\/eje.0.1410117","volume":"141","author":"B Catargi","year":"1999","unstructured":"Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A. Optimized radioiodine therapy of Graves\u2019 disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol. 1999;141:117\u201321. https:\/\/doi.org\/10.1530\/eje.0.1410117.","journal-title":"Eur J Endocrinol"},{"key":"6523_CR5","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1210\/jcem.86.8.7707","volume":"86","author":"VA Andrade","year":"2001","unstructured":"Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves\u2019 hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001;86:3488\u201393. https:\/\/doi.org\/10.1210\/jcem.86.8.7707.","journal-title":"J Clin Endocrinol Metab"},{"key":"6523_CR6","first-page":"25","volume":"14","author":"E Pirnat","year":"2011","unstructured":"Pirnat E, Zaletel K, Gaber\u0161\u010dek S, Hojker S. The outcome of 131I treatment in Graves\u2019 patients pretreated or not with methimazole. Hell J Nucl Med. 2011;14:25\u20139.","journal-title":"Hell J Nucl Med"},{"key":"6523_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/thy.2014.0084","volume":"25","author":"S Sato","year":"2015","unstructured":"Sato S, Noh JY, Sato S, et al. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg\/day and methimazole 30 mg\/day as initial therapy for Graves\u2019 disease patients with moderate to severe hyperthyroidism. Thyroid. 2015;25:43\u201350. https:\/\/doi.org\/10.1089\/thy.2014.0084.","journal-title":"Thyroid"},{"key":"6523_CR8","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2967\/jnumed.112.105148","volume":"53","author":"EB Silberstein","year":"2012","unstructured":"Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53:1633\u201351. https:\/\/doi.org\/10.2967\/jnumed.112.105148.","journal-title":"J Nucl Med"},{"key":"6523_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1530\/eje.1.02158","volume":"154","author":"F Pacini","year":"2006","unstructured":"Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787\u2013803. https:\/\/doi.org\/10.1530\/eje.1.02158.","journal-title":"Eur J Endocrinol"},{"key":"6523_CR10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343\u2013421. https:\/\/doi.org\/10.1089\/thy.2016.0229.","journal-title":"Thyroid"},{"key":"6523_CR11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1089\/thy.2013.0695","volume":"24","author":"M Lee","year":"2014","unstructured":"Lee M, Lee YK, Jeon TJ, et al. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas. Thyroid. 2014;24:1289\u201396. https:\/\/doi.org\/10.1089\/thy.2013.0695.","journal-title":"Thyroid"},{"key":"6523_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1089\/thy.2012.0136","volume":"23","author":"SY Sohn","year":"2013","unstructured":"Sohn SY, Choi JY, Jang HW, et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. Thyroid. 2013;23:741\u20137. https:\/\/doi.org\/10.1089\/thy.2012.0136.","journal-title":"Thyroid"},{"key":"6523_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7762\/cnr.2015.4.4.267","volume":"4","author":"DL Ju","year":"2015","unstructured":"Ju DL, Park YJ, Paik HY, Song Y. The impact of low adherence to the low-iodine diet on the efficacy of the radioactive iodine ablation therapy. Clin Nutr Res. 2015;4:267\u201371. https:\/\/doi.org\/10.7762\/cnr.2015.4.4.267.","journal-title":"Clin Nutr Res"},{"key":"6523_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1590\/2359-3997000000082","volume":"59","author":"VA Santarosa","year":"2015","unstructured":"Santarosa VA, Orlandi DM, Fiorin LB, et al. Low iodine diet does not improve the efficacy of radioiodine for the treatment of Graves\u2019 disease. Arch Endocrinol Metab. 2015;59:501\u20136. https:\/\/doi.org\/10.1590\/2359-3997000000082.","journal-title":"Arch Endocrinol Metab"},{"key":"6523_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/thy.2020.0126","volume":"31","author":"R Nishio","year":"2021","unstructured":"Nishio R, Uchida T, Suzuki L, et al. Influence of short-term dietary and therapeutic iodine restriction on the therapeutic effects of radioactive iodine therapy in patients with Graves\u2019 disease. Thyroid. 2021;31:439\u201345. https:\/\/doi.org\/10.1089\/thy.2020.0126.","journal-title":"Thyroid"},{"key":"6523_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3803\/EnM.2013.28.4.275","volume":"28","author":"JH Moon","year":"2013","unstructured":"Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean Thyroid Association. Endocrinol Metab (Seoul). 2013;28:275\u20139. https:\/\/doi.org\/10.3803\/EnM.2013.28.4.275.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"6523_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.18893\/kakuigaku.oa.1603","volume":"53","author":"M Tamura","year":"2016","unstructured":"Tamura M, Nakada K, Tsuruhara R, et al. Efficacy of dietitian-instructed low iodine diet for radioiodine remnant tissue ablation for thyroid cancer. Kaku Igaku. 2016;53:53\u201360. https:\/\/doi.org\/10.18893\/kakuigaku.oa.1603.","journal-title":"Kaku Igaku"},{"key":"6523_CR18","first-page":"260","volume":"59","author":"LD Marinelli","year":"1948","unstructured":"Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes; practical considerations in therapy and protection. Am J Roentgenol Radium Ther. 1948;59:260\u201381.","journal-title":"Am J Roentgenol Radium Ther"},{"key":"6523_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/clinchem\/46.4.529","volume":"46","author":"T Ohashi","year":"2000","unstructured":"Ohashi T, Yamaki M, Pandav CS, Karmarkar MG, Irie M. Simple microplate method for determination of urinary iodine. Clin Chem. 2000;46:529\u201336.","journal-title":"Clin Chem"},{"key":"6523_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"6523_CR21","doi-asserted-by":"publisher","first-page":"e2065","DOI":"10.1210\/clinem\/dgab919","volume":"107","author":"Y Fuse","year":"2022","unstructured":"Fuse Y, Ito Y, Shishiba Y, Irie M. Current iodine status in Japan: A cross\u2013sectional nationwide survey of schoolchildren, 2014\u20132019. J Clin Endocrinol Metab. 2022;107:e2065\u201379. https:\/\/doi.org\/10.1210\/clinem\/dgab919.","journal-title":"J Clin Endocrinol Metab"},{"key":"6523_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-6614-4-14","volume":"4","author":"TT Zava","year":"2011","unstructured":"Zava TT, Zava DT. Assessment of Japanese iodine intake based on seaweed consumption in Japan: A literature-based analysis. Thyroid Res. 2011;4:14. https:\/\/doi.org\/10.1186\/1756-6614-4-14.","journal-title":"Thyroid Res"},{"key":"6523_CR23","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1210\/jc.2013-4466","volume":"99","author":"K Okamura","year":"2014","unstructured":"Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, Kitazono T. Remission after potassium iodide therapy in patients with Graves\u2019 hyperthyroidism exhibiting thionamide-associated side effects. J Clin Endocrinol Metab. 2014;99:3995\u20134002. https:\/\/doi.org\/10.1210\/jc.2013-4466.","journal-title":"J Clin Endocrinol Metab"},{"key":"6523_CR24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1089\/thy.2014.0581","volume":"25","author":"A Yoshihara","year":"2015","unstructured":"Yoshihara A, Noh JY, Watanabe N, et al. Substituting potassium iodide for methimazole as the treatment for Graves\u2019 disease during the first trimester may reduce the incidence of congenital anomalies: A retrospective study at a single medical institution in Japan. Thyroid. 2015;25:1155\u201361. https:\/\/doi.org\/10.1089\/thy.2014.0581.","journal-title":"Thyroid"},{"key":"6523_CR25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s12020-014-0171-8","volume":"47","author":"T Uchida","year":"2014","unstructured":"Uchida T, Goto H, Kasai T, et al. Therapeutic effectiveness of potassium iodine in drug-na\u00efve patients with Graves\u2019 disease: a single-center experience. Endocrine. 2014;47:506\u201311. https:\/\/doi.org\/10.1007\/s12020-014-0171-8.","journal-title":"Endocrine"},{"key":"6523_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1365-2265.2009.03745.x","volume":"72","author":"K Takata","year":"2010","unstructured":"Takata K, Amino N, Kubota S, et al. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves\u2019 disease. Clin Endocrinol (Oxf). 2010;72:845\u201350. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03745.x.","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06523-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:06:17Z","timestamp":1708502777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06523-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["6523"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06523-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"15 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This retrospective study was approved by the local ethics committees of Nagoya University Hospital (Nagoya, Japan) (2020\u20130052) and Hokko Memorial Hospital (Sapporo, Japan) (I-03) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent to undergo RAI and associated procedures, including adherence to the LID.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}